Endothelin-1 Neutralizing Antibodies for Glomerular Disease Delay
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alport syndrome, a genetic disorder characterized by kidney damage and hearing loss, are symptomatic and lack specific therapeutic agents, with small molecule endothelin-1 antagonists being toxic and ineffective for chronic kidney diseases.
Innovation Solution
Development of neutralizing antibodies that specifically bind to endothelin-1, inhibiting its activity and associated pathologies, including glomerular disease progression and sensorineural hearing loss, using monoclonal antibodies produced by hybridoma cell lines Nab #15 7D 489, Nab #7 3G 9A4, and Nab #1 5D 1087.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule endothelin-1 antagonists are used to treat Alport syndrome, then endothelin-1 activity is inhibited, but toxicity and ineffective treatment occur
Solution Approach 1:
The patent changes the molecular size and structural parameters of the endothelin-1 antagonist from small molecules to large molecule antibodies. This parameter change allows the therapeutic agent to achieve effective inhibition of endothelin-1 activity while avoiding the toxicity associated with small molecule inhibitors, as the antibody-based approach provides selective binding and neutralization with better safety profiles.
Solution Approach 2:
The patent employs composite biological molecules (antibodies) rather than simple small molecule compounds. The antibody structure provides a composite system with multiple binding sites and functional regions that enable effective endothelin-1 neutralization while improving safety and reducing toxicity compared to conventional small molecule antagonists.
2Ease of operation
If current symptomatic treatments are used for Alport syndrome, then management of complications is achieved, but no specific therapeutic progress is made
Solution Approach 1:
The patent applies preliminary action by using antibodies that can neutralize endothelin-1 before it causes damage to the glomerular basement membrane. The antibody therapy acts preventively by blocking endothelin-1 binding to its receptors, thereby preventing the initiation of fibrotic processes and glomerulosclerosis rather than merely managing symptoms after damage has occurred.
Solution Approach 2:
The patent converts the harmful effect of endothelin-1 (which drives fibrosis and glomerulosclerosis) into a beneficial target for therapy. By developing antibodies that specifically neutralize endothelin-1, the therapy transforms the disease-driving molecule into a target for protective intervention, thereby achieving specific therapeutic progress rather than merely symptomatic management.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies delay the onset and progression of glomerular disease, reduce fibrosis, and ameliorate structural abnormalities in Alport syndrome, providing a safer therapeutic option than small molecule inhibitors.
Implementation Method 1
an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1
Data Source
AI summary
This application provides antibodies and functional equivalents thereof which are capable of neutralizing endothelin-1, as well as their use in the treatment of disease conditions associated with endothelin-1 activation, such as Alport syndrome.